Cue Biopharma, Inc.: Cormorant Asset Management, LP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Cormorant Asset Management disclosed a stake exceeding 5% in Cue Biopharma via a Schedule 13G filing with the SEC (accession 0001172661-26-005293). The exact share count and percentage were not specified in the filing headline. The move signals renewed institutional interest in the clinical-stage immunotherapy developer. Investors will watch for further 13G/13D amendments and any changes in Cormorant's position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Cormorant Asset Management, LP, Cue Biopharma, Inc.